Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Aligos Therapeutics presented positive Phase 1 follow-up data for pevifoscorvir sodium showing sustained reductions in HBV viral markers and cccDNA reservoir. The company reported that 40% of HBeAg+ participants achieved HBsAg levels below 3,000 IU/mL at week 48, potentially qualifying them for functional cure therapy. Preclinical data demonstrated additive to synergistic effects when combining pevifoscorvir sodium with the ASO ALG-170675.

05/27/2026, 2:30 AM • GlobeNewswire

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic hepatitis B in Greater China. Aligos will receive a $25M upfront payment and up to $420M in milestone payments plus royalties, while retaining rights in the US, Europe, Japan, and South Korea. The deal extends Aligos' cash runway into Q4 2026.

04/16/2026, 6:00 AM • GlobeNewswire

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Aligos Therapeutics reported significant progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B, completing enrollment of HBeAg- participants with interim analyses expected in 2026. The company also advanced ALG-170675, a dual-mechanism antisense oligonucleotide, into IND-enabling studies in partnership with Xiamen Amoytop Biotech. ALG-055009 showed synergistic weight loss results when combined with incretin receptor agonists. Full year 2025 net loss improved to $24.2 million from $131.2 million in 2024, with cash and investments of $77.8 million expected to fund operations into Q3 2026.

03/05/2026, 8:00 AM • GlobeNewswire

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

Aligos Therapeutics announced positive clinical data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver. The company presented Phase 1 monotherapy data for pevifoscorvir sodium, a potential first-/best-in-class CAM-E for chronic hepatitis B virus infection, showing high viral suppression. Additionally, Aligos presented pharmacokinetic data for ALG-097558, a pan-coronavirus protease inhibitor, in patients with renal and hepatic impairment.

02/23/2026, 8:00 AM • GlobeNewswire

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics announced that its Compensation Committee granted non-qualified stock options to purchase 81,100 shares to newly hired employees on January 29, 2026, as an inducement for employment. The options have an exercise price equal to the closing stock price on the grant date and will vest over four years with 25% vesting on the first anniversary.

01/30/2026, 8:00 AM • GlobeNewswire

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics granted non-qualified stock options to purchase 14,100 shares for newly hired employees under their 2024 Inducement Plan, with shares vesting over a four-year period.

12/12/2025, 8:00 AM • GlobeNewswire

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics announced granting non-qualified stock options to newly hired employees, with 23,600 shares to be vested over a four-year period under their 2024 Inducement Plan.

11/14/2025, 8:00 AM • GlobeNewswire